The earnings call reflects a strong performance with significant revenue growth and improved margins. The company is well-positioned in international markets with a solid cash position and no debt. However, there are challenges in the consumer cannabis segment, increased SG&A, and potential regulatory challenges in international markets.

Company Guidance

During Aurora Cannabis Inc.'s fiscal first quarter 2026 results conference call, the company reported a 17% year-over-year increase in net revenue to $98 million, with global medical cannabis revenue rising by 37% and international revenue growing by 85%. This growth contributed to an adjusted gross margin improvement of 1,000 basis points to 52%, and adjusted EBITDA more than doubled to $11 million. The company also generated a positive free cash flow of $9 million. Aurora highlighted its strong cash position of $186 million and emphasized its debt-free cannabis business, asserting no need to dilute shareholders through capital raises. For the second quarter of fiscal 2026, Aurora expects consolidated net revenue to grow by 8% to 12% year-over-year, driven primarily by its Global Medical Cannabis segment, with continued improvements in adjusted gross margins and positive adjusted EBITDA anticipated.

Revenue Growth and Strong Financial Performance

Net revenue rose 17% to $98 million with global medical cannabis revenue increasing 37%. International revenue grew 85%, and adjusted EBITDA more than doubled to $11 million.

Improved Margins and Cash Flow

Adjusted gross margin improved 1,000 basis points to 52%, and positive free cash flow of $9 million was generated. The company holds a cash balance of $186 million with no cannabis business debt.

Market Leadership and Global Expansion

Aurora is the largest Canadian exporter of high-quality medical cannabis with a strong presence in Canada, Australia, Germany, Poland, and the U.K.

Operational Efficiency and Cost Management

Lower production costs achieved through yield improvement and operational efficiencies with investments in cultivation technology.

Positive Outlook for Future Growth

Consolidated net revenue expected to increase year-over-year with continued positive adjusted EBITDA growth and strong international market performance.

Aurora Cannabis (TSE:ACB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:ACB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2026 (Q2)	0.02 / -	-0.22	―	―	―
Aug 06, 2025	2026 (Q1)	0.16 / -0.26	0.08	-425.00% (-0.34)
Jun 18, 2025	2025 (Q4)	0.13 / -0.35	-0.4	12.50% (+0.05)
Feb 05, 2025	2025 (Q3)	<0.01 / 0.57	-0.5	214.00% (+1.07)
Nov 06, 2024	2025 (Q2)	-0.11 / -0.22	0	―
Aug 07, 2024	2025 (Q1)	-0.17 / 0.08	-0.8	110.00% (+0.88)
Jun 20, 2024	2024 (Q4)	-0.18 / -0.40	13.626	-102.94% (-14.03)
Feb 08, 2024	2024 (Q3)	-0.13 / -0.50	-2.5	80.00% (+2.00)
Nov 09, 2023	2024 (Q2)	- / 0.00	-2	―
Sep 26, 2023	2023 (Q4)	- / -	-0.17	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:ACB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	C$6.34	C$5.81	-8.36%
Jun 18, 2025	C$8.02	C$6.40	-20.20%
Feb 05, 2025	C$5.28	C$7.65	+44.89%
Nov 06, 2024	C$8.46	C$7.11	-15.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.